Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06427878 in Overweight-Obese Adults
NCT02855177Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperlipidemia and Nonalcoholic steatohepatitis (NASH) comparing Placebo with PF-06427878 (2 arms). Primary endpoints: Number of Treatment Emergent Treatment-Related Adverse Events, Change from baseline in clinical laboratory tests and 2 more. Started Aug 2016; status: completed.
02
Drugs
PF-06427878
03
Conditions
hyperlipidemiaNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02855177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02855177.